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Introduction
Malignant melanoma represents 1% of all neoplasms in
men, and 1.5% in women in Poland. In 98% of cases it
primarily affects the skin. The standardised incidence
rates are 2.5/100.000 for men, and 2.6/100.000 for women,
and the standardised mortality rates are 1.5/100.000 and
1.2/100.000, respectively [1, 2]. The incidence of malignant
melanoma is increasing steadily, some epidemiological
studies even show its twofold increase in every decade
[1, 3, 4].
The treatment of choice is surgery. Radiotherapy is
used for incompletely removed primary tumours,
inoperable local recurrences and skin, nodal, bone and
cerebral metastases [1, 3, 5, 6]. Due to the rather
disappointing results of radiotherapy, malignant
melanoma was believed to be a neoplasm of low
radiosensitivity. However, the use of high dose per
fraction (hypofractionation) renewed interest in this
treatment [7, 8].
The aim of this study is to evaluate the role of
palliative radiotherapy in the treatment brain metastases
of malignant melanoma of the skin.
Material and methods
Between 1990 and 2000, twenty melanoma patients (14 men, 6
women; mean age 48 years; range 27 – 76 years) with brain
metastases were palliatively irradiated at the Maria Sk∏odowska-
Curie Memorial Cancer Center and Institute of Oncology in
Kraków. Mean history of melanoma was 7 months (range:1 – 24
months), and the mean Karnofsky performance status was 80%
(range: 60% – 90%).
In 7 patients, the primary tumour was located on the trunk,
in another 7 – on the extremities, in 4 – in the head and neck
NOWOTWORY Journal of Oncology • 2004 • volume 54
Number 1 • 28–30
Radiotherapy of malignant melanoma cerebral metastases 
– results of treatment
Katarzyna Pude∏ek, Jan Sko∏yszewski
A i m.  The aim of the study was to evaluate the efficacy of radiotherapy in the treatment of malignant melanoma brain
metastases.
M a t e r i a l  a n d  m e t h o d s.  20 patients with malignant melanoma brain metastases treated with palliative radiotherapy at
the Centre of Oncology in Kraków between 1990 and 2000. In 8 cases the patients were irradiated twice daily (39 Gy in 13
fractions of 300 cGy) and in 12 cases once daily (20-40 Gy in 5-10 fractions of 400 cGy).
Re s u l t s.  The overall 2-year survival rate in the entire group of 20 palliatively irradiated patients was 5%. The median survival
was 5.5 months.
C o n c l u s i o n.  Radiation therapy is effective in the palliative management of malignant melanoma brain metastases.
Wyniki leczenia napromienianiem chorych
z przerzutami czerniaka z∏oÊliwego do mózgu
C e l.  Ocena roli radioterapii w leczeniu chorych na czerniaka z∏oÊliwego z przerzutami do mózgu na podstawie doÊwiadczeƒ
Centrum Onkologii w Krakowie.
M a t e r i a ∏  i m e t o d y.  W latach 1990-2000 w Centrum Onkologii w Krakowie leczono napromienianiem 20 chorych na
czerniaka z∏oÊliwego skóry z przerzutami do mózgu. U wszystkich chorych zastosowano paliatywne napromienianie ca∏ego
mózgu. 8 chorych napromieniano dwa razy dziennie dawkà 39 Gy w 13 frakcjach po 300 cGy. 12 chorych napromieniano raz
dziennie i otrzymali oni dawk´ 20-40 Gy w 5-10 frakcjach po 400 cGy.
W y n i k i.  W ca∏ej omawianej grupie odsetek prze˝yç dwuletnich wyniós∏ 5%. Mediana prze˝ycia wynios∏a 5.5 miesi´cy.
W n i o s e k.  Radioterapia jest skutecznà metodà paliatywnego leczenia chorych z przerzutami czerniaka z∏oÊliwego do
mózgu.
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region, while in 2 cases the location of the primary tumour
remained unknown. All our patients had brain metastases and
stage IV disease, according to the UICC classification [9]. Brain
metastases were the only localization of disease at the time of
treatment. 
In our group of 20 patients radiotherapy was the only
treatment method of brain metastases, all were treated with
whole brain megavoltage Co60 radiotherapy; 12 patients were
irradiated with a 400cGy dose per fraction – 10 patients received
a total dose of 20 Gy in 5 fractions and 2 received 40 Gy in 10
fractions. The remaining 8 patients were irradiated twice daily
with a 300 cGy dose per fraction, receiving a total tumour dose
of 39 Gy in 13 fractions over 8.5 days of treatment (they were not
irradiated during weekends). The interval between the fractions
was at least 6 hours.
During irradiation 16 patients received corticosteroids
either for increased intracranial pressure or to reduce the risk of
radiation-induced oedema of the brain; 14 patients received
dexamethasone orally (12 mg per die), and 2 patients received
intravenous dexamethasone (24 mg per die). Thirteen patients
received 100 mg of Phenobarbital orally, to prevent seizures;
(6 patients once daily and 7 – twice daily).
Patient survival was determined from day 1 of radiotherapy
to the day of death. At the time of this analysis, all 20 patients
were dead; in all cases the date of death was known. Overall
survival was calculated using the Kaplan-Meier method and the
chi square test was used to compare the survival rates.
Results
One patient (5%) survived two years. The curve depicting
the overall survival of our patients is shown in Figure 1.
The median survival of 20 patients with brain
metastases estimated from the onset of radiotherapy, was
5.5 months. Survival was longer (median of 7.5 months) in
those 8 patients who were irradiated twice daily with
a 300 cGy dose per fraction, as compared with the 12
patients irradiated once daily with a 400 cGy dose per
fraction (median – 3 months). However, the difference is
not statistically different, probably due to the small
number of patients. The curves comparing the overall
survival of patients irradiated twice daily and once daily
are shown in Figure 2.
Radiotherapy was well tolerated, no patient
developed severe acute side effects following irradiation.
All our patients eventually died of distant metastases.
Discussion
The results of therapy of melanoma cerebral metastases
are poor and the choice of optimal treatment modalities
remains a problem. Some authors believe that surgery
combined with radiotherapy could improve treatment
results [10,1 1].
Rate et al. presented results of radiotherapy for
metastatic malignant melanoma to the brain and to the
bones. The median survival of 77 patients with brain
metastases was 14 weeks. Statistically improved survival
was observed in patients who underwent subtotal or total
resection of a solitary brain metastasis prior to radio-
therapy (median – 36 weeks); while no improved survival
was observed in patients with a solitary brain metastasis
treated by radiotherapy alone (median – 16 weeks) [11].
Seegenschmiedt et al. presented their 20-year clinical
experience with palliative radiotherapy in 121 patients
with locally advanced, recurrent or metastatic malignant
melanoma in stages UICC IIB/III/IV. The patients
received a total dose of 20-66 Gy, fraction dose 2-6 Gy.
Complete response was achieved in 17% of the UICC
IV patients. On the last follow-up, 6% of the UICC IV
patients were still alive. External beam radiotherapy
provided effective palliation in malignant melanoma. The
UICC staging system was an excellent prognostic factor
for tumour response [12].
Ellerhost et al. presented results of whole brain
irradiation in 87 patients with metastatic melanoma. The
median survival of the entire populace was 19 weeks.
Improved survival was noted in patients who underwent
resection of all brain metastases (45 weeks) and in those
with no extracranial disease (45 weeks). The authors
suggest that whole brain irradiation may provide pallia-
tion for melanoma patients with brain metastases [10].
Kirova et al assessed the response rate and efficacy
of palliative radiation therapy in patients with metastatic
melanoma. Nine patients had brain metastases and were
treated with 30 Gy of irradiation in 10 fractions or 20 Gy
in 5 fractions. 57% of the patients with brain metastases
had remission and good palliation of symptoms, 29% did
not respond, and 1 patient showed aggravation of disease.
Thus, the authors believe that short-course radiotherapy
has a role to play in the palliation of metastatic melanoma
[13].
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Figure 1. Overall survival in 20 patients treated with palliative
radiotherapy for brain metastases of malignant melanoma
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Figure 2. The survival of patients irradiated once daily vs. twice daily
It is difficult to compare the results of radiotherapy
presented in literature, as the groups of patients treated in
different centres are highly diversified. In our study, the
overall 2-year survival of the entire group was 5%, and
was similar to the results published by other authors.
Patients receiving palliative radiotherapy for metastatic
malignant melanoma to the brain survived 6 months. Our
results suggest that radiotherapy may be effective in the
palliative management of brain metastases. Better results
obtained in the group of patients irradiated twice daily
should be confirmed in further studies. Similarly to Rate
and Ellerhost [10, 11] we have proven the efficacy of
palliative radiotherapy in metastatic disease.
In all our patients, distant metastases were the
ultimate cause of treatment failure. This observation is in
keeping with the data of the other authors [11, 12]. Thus,
it seems that the possible improvement of results is to
be looked for in the new and better methods of systemic
therapy.
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